Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dienestrol is a synthetic nonsteroidal estrogen of the stilbestrol group. It acts as an estrogen receptor agonist and is used primarily to treat atrophic vaginitis and kraurosis vulvae in women. Mechanistically similar to other estrogens such as diethylstilbestrol (DES), dienestrol binds to estrogen receptors in target tissues—including the female reproductive tract—leading to increased gene transcription and protein synthesis associated with estrogenic effects. It was introduced in the United States by Schering as Synestrol in 1947 and has been marketed under various brand names worldwide. In addition to its primary indications for menopausal symptoms (such as vaginal dryness or inflammation), it has also been studied for use by rectal administration in prostate cancer treatment for men[1][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dienestrol.